February 12th, 2015
11am

Sponsored by

Webinar Description:

While personalized medicine in Oncology is now a reality, widespread adoption in the community still remains a challenge. With that, a large number of organizations have emerged that are now offering services to help individualize cancer therapy in the clinic as well as to BioPharma for clinical development efforts. The purpose of this symposium is to review some key technical learnings obtained through key laboratory and bio-specimen work on The Cancer Genome Atlas Project and how Paradigm and how new biosciences organization, Paradigm, has applied them in the development of their NGS-based tumor profiling service, Paradigm Cancer Diagnostic (PCDx).

Learning Objective Bullet Points:

• Understand the history, role and importance of tumor profiling for rare, aggressive and refractory cancers.
• Understand the importance of depth of coverage (DOC) and specimen quality in targeted gene sequencing for clinical patient care.
• Become familiar with the importance and emerging role of mRNA.
• Understanding the importance and opportunity of Molecular Tumor Boards to help drive personalized medicine in the community setting.
• Gain familiarity with the features and benefits of the Paradigm PCDx service.

Who Should Attend:

• Oncologists
• Pathologists
• Oncologic Surgeons
• BioPharma Clinical Research
• Investor Community

Program Agenda:

11:00-11:45 – Dr. Robert Penny, MD, PhD, CEO
11:45-12:00 - Questions

Speaker Information

Robert Penny, MD, PhD, CEO, Paradigm

Dr. Robert Penny is the Co-founder and Chief Executive Officer of The International Genomics Consortium (IGC). He has served as a board member for the IGC, its Chief Medical and Operating Officer and the Executive Director of the IGC’s national Expression Project for Oncology (expO). Dr. Penny is the Principal Investigator for the Biospecimen Core Resource (BCR) for the full The Cancer Genome Atlas Project (TCGA) and a separate award for TCGA’s Tissue Source Site network.

While at the IGC, he founded the Molecular Profiling Institute and served as its Chief Executive Officer and Chairman of the Board. The Molecular Profiling Institute is the first company to commercially introduce gene expression analysis into oncology in the U.S. He developed the Molecular Profiling Institute’s portfolio of molecular testing and pharmaceutical services which includes his successful commercially available holistic genomic analysis of cancer with its award-winning surgical oncology report (Target Now) that matches molecular mechanisms with associated oncology therapies. He led the successful merger of the Molecular Profiling Institute to Caris Life Sciences.

Dr. Penny is also the CEO of Paradigm Diagnostics and is a recognized expert in the translation of diagnostics into patient care as well as in biorepositories. He has established two national esoteric reference medical laboratories, a national tissue bank and analysis center, and a national genomics program. He has helped bring cellular and molecular diagnostic, prognostic and therapeutic testing to patient care throughout the nation with leukemia, lymphoma and solid tumors. He has headed up genomic strategies for the nation’s largest medical diagnostic corporations and chaired committees for TCGA leadership.The College of American Pathologists awarded Dr. Penny the national organization’s 2012 Distinguished Patient Care Award for his extensive scientific translational research to accelerate the adoption of molecular pathways and associated therapies into the field of pathology and oncology to improve the lives of cancer patients.

In 2011, the AZ BioIndustry Association honored Dr. Penny with the Jon W. McGarity Leadership Award for his vision in advancing cancer personalized medicine and success in leading the industry. The AZ BioIndustry Association also presented the IGC with a 2011 Fast Lane Award for moving the industry forward.

In 2005, Dr. Penny won the AZ BioIndustry Association’s Lifescience Executive of the Year Award for Excellence in the BioIndustry.
Dr. Penny received his B.S., M.S., Ph.D. (Genetics) and M.D. from the University of Arizona and then went on to receive his pathology training at Harvard’s Brigham & Women’s Hospital in Boston, Massachusetts, where he served as Chief Resident and completed fellowships in hematopathology and surgical pathology. Dr. Penny’s contributions include a textbook in oncology, publication of articles and leadership roles in laboratory management.

Schedule conflict? Register and you'll receive a copy of the recording